Markets

Ocera Therapeutics (OCRX) Catches Eye: Stock Jumps 6.8%

Ocera TherapeuticsOCRX was a big mover last session, as the company saw its shares rise almost 7% on the day. The move came on solid volume with far more shares changing hands than in a normal session. This breaks the recent trend of the company since Dec 7, as the stock is now trading above the volatile price range of $2.10 to $2.30.

In the last 30 days, the company has seen no estimate revision but the Zacks Consensus Estimate moved lower, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward to see if this recent move higher can last.

Ocera Therapeutics currently carries a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%.

OCERA THERAPEUT Price

OCERA THERAPEUT Price | OCERA THERAPEUT Quote

Another well-ranked Medical-Biomedical & Genetics stock is Amarin Corporation plc AMRN , which flaunts a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .

Is OCRX going up? Or down? Predict to see what others think: Up or Down

Zacks' Top 10 Stocks for 2017

In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2017? Who wouldn't? As of early December, the 2016 Top 10 produced 5 double-digit winners including oil and natural gas giant Pioneer Natural Resources which racked up a stellar +50% gain. The new list is painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. Be among the very first to see it>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

AMARIN CORP PLC (AMRN): Free Stock Analysis Report

OCERA THERAPEUT (OCRX): Free Stock Analysis Report

To read this article on Zacks.com click here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

AMRN

Other Topics

Investing Stocks

Latest Markets Videos